C.Q. Pharmaceutical Holding (000950.SZ): "MIRABERLONG sustained-release tablets" obtained the drug registration certificate.

C.Q. Pharmaceutical Holding (000950.SZ) announced that its subsidiary Chongqing Pharmaceutical (Group) Co., Ltd. ("Chongqing Medicine") recently received the Drug Registration Certificate issued by the National Medical Products Administration for the product: "Mirtazapine Extended-Release Tablets". Chongqing Medicine carries out drug research and production in the form of a Marketing Authorization Holder (MAH) and strictly controls the quality and safety of the drug throughout its lifecycle. With the approval of the registration of Mirtazapine Extended-Release Tablets, the company can now produce and sell the product domestically, further enriching its portfolio of formulations. This will complement the company's traditional drug distribution business and enhance its market competitiveness. Additionally, according to national regulations, the production approval of Mirtazapine Extended-Release Tablets as a Category 4 chemical drug through consistency evaluation will facilitate the expansion of the company's product sales, positively impacting its future business performance.